TrialBritish journal of haematology2017

A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.

Connie L Batlevi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.